Hematopoietic progenitor cells arising from bone marrow (BM) are known to contribute to the formation and expansion of tumor vasculature. However, whether different subsets of these cells have different roles in this process is unclear. To investigate the roles of BM-derived progenitor cell subpopulations in the formation of tumor vasculature in a Ewing's sarcoma model, we used a functional assay based on endothelial cell and pericyte differentiation in vivo. 
Hematopoietic progenitor cells arising from bone marrow (BM) are known to contribute to the formation and expansion of tumor vasculature. However, whether different subsets of these cells have different roles in this process is unclear. To investigate the roles of BM-derived progenitor cell subpopulations in the formation of tumor vasculature in a Ewing's sarcoma model, we used a functional assay based on endothelial cell and pericyte differentiation in vivo. Fluorescence-activated cell sorting of human cord blood/BM or mouse BM from green fluorescent protein transgenic mice was used to isolate human CD34 + / CD38 + , Sca1 À /Gr1 + , VEGFR1 + , and VEGFR2 + cells. Each of these progenitor subpopulations was separately injected intravenously into nude mice bearing Ewing's sarcoma tumors. Tumors were resected 1 week later and analyzed using immunohistochemistry and confocal microscopy for the presence of migrated progenitor cells expressing endothelial, pericyte, or inflammatory cell surface markers. We showed two distinct patterns of stem cell infiltration. Human CD34 + /CD45 + and CD34 + / CD38 À and murine VEGFR2 + and Sca1 + /Gr1 + cells migrated to Ewing's tumors, colocalized with the tumor vascular network, and differentiated into cells expressing either endothelial markers (mouse CD31 or human vascular endothelial cadherin) or the pericyte markers desmin and A-smooth muscle actin. By contrast, human CD34
Introduction
The creation and expansion of a functional vascular network is essential for tumor growth. Aggressive malignancies, such as Ewing's sarcoma, depend on angiogenesis and vasculogenesis to support the rapid rate of tumor cell proliferation (1) . Therefore, understanding how tumor vessels expand to support the nutritional and oxygen needs of the tumor may identify novel therapeutic targets to interfere with this process. Endothelial progenitor cells (EPC) have been shown to participate in postnatal vasculogenesis (2) . However, defining a set of markers that uniquely identifies these cells has generated much controversy. No clear designation exists for when an EPC becomes a mature endothelial cell, and a universally accepted functional assay for these cells is also lacking. Consequently, several types of assays have been used to show that diverse cell types possess EPC-like capacity. Traditionally, EPCs were believed to express CD34, AC133, and vascular endothelial growth factor receptor 2 (VEGFR2; refs. 2-4). However, it has also been argued that the majority of EPCs are derived from monocytes/macrophages, which are CD34 À (5) . A specific subset of CD14 + monocytes, those that express VEGFR2, was described to have endothelial differentiation capacity (6) . CD34 + /VEGFR3 + progenitor cells were reported to play a role in lymphangiogenesis (7) . Even mesenchymal stem cells have been shown to form endothelial cells in the presence of VEGF and serum in vitro (8) .
Direct stem/progenitor cell incorporation into the endothelial lining of functional tumor neovessels has been reported (9) . In addition, recent investigations have shown that bone marrow (BM) cells may have other functions within the tumor microenvironment. Platelet-derived growth factor receptor-h -expressing pericyte progenitor cells were shown to differentiate into NG2 + , desmin + , and a-smooth muscle actin -positive (SMA + ) pericytes within the tumor vasculature (10). De Palma et al. (11, 12) reported that Tie-2 -expressing monocytes homed to tumors in mice and promoted angiogenesis in a paracrine fashion. Similarly, Gr + /CD11b + myeloid immune suppressor cells homing to tumors were found not only to directly incorporate into tumor endothelium but also to promote tumor angiogenesis and growth indirectly via release of matrix metalloproteinase-9 (13) .
The extent of BM cell incorporation into tumors may be highly variable and depend on the specific tumor model or the quantity/type of BM cells injected (9) . Few studies have investigated more than one stem/progenitor cell subpopulation. To clarify the roles of various types of EPCs in tumor vasculogenesis, we investigated the participation of different BM-derived progenitor cell subpopulations in a murine model of Ewing's sarcoma tumors. We chose this model because we previously showed that Ewing's tumors recruit BM-derived progenitor cells, which participate in tumor vessel formation (1, 14 (Fig. 2B , Merge, blue cells). To determine whether stem cells also contributed to pericyte formation, tumor sections were costained for gfp and the pericyte differentiation markers a-SMA and desmin and then analyzed by confocal microscopy (Fig. 2C) . CD34 + /CD38 À cells expressing a-SMA or desmin were detected in the tumor vascular network, indicating that a fraction of this migrated progenitor subpopulation had differentiated into pericytes/vascular smooth muscle cells (Fig. 2C , arrows). + subpopulations were isolated from fresh gfp + BM using fluorescence-activated cell sorting ( Fig. 1 ) and then intravenously injected separately into tumor-bearing mice. Mice were sacrificed 1 week later, and tumors were excised and analyzed by immunohistochemistry. The migrated murine BM progenitor subpopulations were detected using anti-gfp. All four subpopulations migrated to the tumor. However, their distributions within the Ewing's tumors varied. As shown in Fig. 3A , migrated VEGFR2 + cells (red) were detected throughout the tumor area, predominantly in the vicinity of tumor vessels (green). Yellow fluorescence in the merged image (Fig. 3A, arrows) showed that some of the migrated VEGFR2 + cells expressed CD31, indicating they had differentiated into mouse endothelial cells. gfp + cells expressing desmin (data not shown) and a-SMA (Fig. 3B ) were also present within the vasculature, indicating that some of the VEGFR2 + progenitor cells had differentiated into pericytes/vascular smooth muscle (Fig. 3C ) migrated into the tumor and were associated with CD31 + microvessels. Using confocal microscopy, we showed that Sca1 + /Gr1 + cells differentiated into CD31 + endothelial cells (purple cells) and were directly incorporated into vessels, thereby forming a mosaic pattern of BM progenitor-derived (purple) and locally derived (blue) endothelial cells adjacent to each other within the vascular endothelial lining (Fig. 3C, left) . Sca1 + /Gr1 + -derived cells expressing a-SMA (Fig. 3C , right, arrow) and desmin (data not shown) were also seen, indicating pericyte differentiation. 
Migrated VEGFR1
+ -derived cells were found in close proximity to CD31 + tumor vessels as well as away from the vessels (data not shown). However, these VEGFR1 + -derived cells did not express CD31, again indicating that this murine BM subpopulation did not differentiate into endothelial cells within Ewing's sarcoma tumors (Table 1) .
Discussion
The data presented show that both human and mouse BMderived stem/progenitor subpopulations fall into two categories: those that differentiate into endothelial cells and pericytes and participate in Ewing's sarcoma tumor neovasculature formation and those that differentiate into myeloid cells and do not contribute to tumor vessel development. We showed that human CD34 + /CD38 progenitor subpopulations contributed to the tumor vessel architecture, our findings refute the contention that migration of progenitor cells to human tumors is nonspecific. CD34 + -derived human endothelial cells were observed wrapped around the tumor vessels and seemed distinct from the tumor vessel mouse endothelium. For this reason, we were concerned that species mismatch may interfere with the ability of recruited human progenitor cells to interact with the local mouse endothelial cells in the formation of tumor vessels. We therefore also evaluated whether mouse BM-derived stem/ progenitor subpopulations showed a similar pattern of migration and differentiation. Sca1 is a marker of hematopoietic stem cells found in the mouse BM, whereas Gr1 is a myeloid differentiation antigen ( + -and Sca1 + /Gr1 + -derived cells were within the expanding tumor vascular network. It is unclear at this point if these cells proliferated once within the tumor tissue or whether the large clusters of BM-derived cells resulted solely from migration. A portion of the VEGFR2 + -and Sca1 + /Gr1 + -derived cells colocalized with CD31 and incorporated into tumor vessels, indicating that they had differentiated into endothelial cells (Fig. 3A and C) . A substantial fraction, however, resided in very close proximity to tumor vessels but did not express CD31. Rather, these recruited Sca1 + /Gr1 + -and VEGFR2 + -derived cells expressed the pericyte markers a-SMA and desmin ( Fig. 3B and C) . These data indicate that, similar to human CD34 + cells, these mouse BM subsets also contribute to the tumor vessel pericyte/vascular smooth muscle cell network. More importantly, our confocal studies ( Fig. 3B and C) indicate for the first time that the endothelial and smooth muscle cell components of the tumor vasculature are mosaics composed of both BM and locally derived cells. Indeed, the vessel wall is composed of BM-derived and local endothelial cells side by side. This finding suggests that BM cells play an important, perhaps even critical, role in tumor vessel formation and that the BM serves as a source for the needed progenitor cells as the tumor vasculature expands during tumor growth. Interestingly, the incorporation of BM-derived cells in tumor vessels is not a uniform process, and these cells do not distribute homogeneously throughout the tumor tissue. Rather, recruited BMderived cells form ''hotspots'' of incorporation at distinct sites within the tumor neovasculature. In our analysis of the Ewing's tumor vasculature, certain microscopic tumor fields were found to contain numerous BM-derived endothelial cells and pericytes, with nearby microscopic fields often showing a relative absence of BM-derived cells. Previous work in our laboratory has shown that, on average, 10% of Ewing's tumor vessels contain at least one BM-derived cell (1).
Our findings are consistent with other recent reports showing that BM-derived cells differentiate into tumor pericytes in melanoma, pancreatic carcinoma, and neuroblastoma (10, (15) (16) (17) . Pericytes envelop the endothelial lining of blood vessels, supporting and regulating blood vessel formation Expressed by a subpopulation of hematopoietic stem cells; receptor for VEGF and placental growth factor (15) . Pericytes in tumor blood vessels provide an escape mechanism to antiangiogenic therapy by promoting endothelial cell survival/stability (18 À /Gr1 + cells differentiated into macrophages/monocytes within the TC71 microenvironment. As was the case for the BM-derived endothelial cells and pericytes described above, BM-derived macrophages did not seem to distribute uniformly throughout the tumor tissue. Although distinct areas within the Ewing's tumor showed an abundance of BM-derived macrophages, other areas showed many host-derived (non -graft derived) macrophages. Although these specific BM subpopulations seem to play no role in the formation of tumor vessels, they nevertheless may have a different role that contributes to tumor cell growth and survival. Macrophage/monocyte progenitors may promote tumor growth via the production of angiogenic factors. For example, human stem/progenitor cells expressing monocyte/macrophage markers have previously been shown to secrete VEGF, hepatocyte growth factor, granulocyte colony-stimulating factor, and granulocyte-macrophage colony-stimulating factor (4). Furthermore, Bingle et al. (19) used breast cancer spheroids to show that macrophages can initiate tumor angiogenesis in vivo. Not only have tumor-infiltrating macrophages been linked to tumor progression (20) but specifically eliminating these cells suppressed tumor growth and metastasis (21, 22) . Targeting the specific BM stem/progenitor cell types that migrate to tumors and promote tumor growth by differentiating into macrophages may represent another potential therapeutic approach.
The objective of these studies was to determine whether specific BM subpopulations contributed to the formation of the tumor neovasculature. We have shown that human CD34 + hematopoietic stem cells and the mouse counterpart Sca1 + /Gr1 + cells are the key progenitor cells that contribute to tumor vessel formation and that these cells migrate to the tumor and differentiate into either endothelial cells or pericytes. It is impossible to uniquely label each individual BM subset within a single animal and distinguish their individual contributions to the tumor vasculature. We therefore characterized each BM subpopulation of interest separately in a tumor-bearing animal.
It is important to note that the surface markers expressed by the BM-derived subpopulations analyzed are certainly not mutually exclusive. Specifically, we showed that 52.5% of VEGFR2 + cells were also Sca1 + , whereas 58.2% of Sca1 + cells coexpressed VEGFR2. In addition, 8.5% of Sca1 + cells also expressed VEGFR1, whereas 38.5% of VEGFR1 + cells coexpressed Sca1. Six percent of VEGFR2 + cells were also VEGFR1 + , whereas 29.4% of VEGFR1 + cells coexpressed VEGFR2.
Determining the relative importance of each subpopulation is beyond the scope of this work and cannot be ascertained by the methodology described. As an initial step toward comparing various progenitor subpopulations, an equal number of sorted cells of each type could be intravenously injected into tumor-bearing mice and the relative numbers of migrated cells were assessed. However, the detection of a larger number of migrated cells of a particular type within the tumor may not necessarily equate to greater importance. It is likely that the migrated cells divide, and the present detection system cannot identify daughter cells from parental migrated cells. 
Materials and Methods

Ewing's Sarcoma Cell Lines
TC71 human Ewing's sarcoma cells were cultured in Eagle's MEM supplemented with 10% fetal bovine serum, 2 mmol/L L-glutamine, 1 mmol/L nonessential amino acids, 1 mmol/L penicillin-streptomycin, and 2-fold vitamin solution (Life Technologies). These cells have the Ewing's sarcoma t (11; 22) translocation as detected by reverse transcription-PCR.
Mice and Murine BM Cells
All experiments were approved by the Institutional Animal Care and Use committee of the University of Texas M. D. Anderson Cancer Center. All animals were housed in a specific pathogen-free facility. Four-to six-week-old athymic (T-cell deficient) nu/nu nude mice were purchased from the National Cancer Institute. gfp transgenic mice (strain 003115; The Jackson Laboratory) were purchased from M. D. Anderson Cancer Center, Genetic Engineering Mouse Facility. This transgenic strain expresses an enhanced gfp driven by chicken h-actin promoter and cytomegalovirus intermediate early enhancer; intensity of gfp expression varies in a tissuedependent manner. gfp transgenic mice were used as BM donors. BM cells were isolated from donors by flushing hind femurs with PBS. Freshly isolated BM cells were resuspended in PBS and kept on ice until injected into the tail veins of recipient nude mice.
Isolation of Human and Murine Stem/Progenitor Cell Subpopulations
Human CD34 + cells were isolated from umbilical cord blood obtained from the St. Louis Cord Blood Bank (St. Louis, MO) as previously described (14) . Alternatively, frozen BM-derived CD34 + cells were purchased from the National Disease Research Interchange (Philadelphia, PA). CD34 + cells were cultured at 37jC in serum-free expansion medium (Stemcell Technologies) supplemented with Flt3 ligand, stem cell factor, interleukin-3, and interleukin-6 (StemSpan CC100 cytokine cocktail, Stemcell Technologies). Culture-expanded CD34 + cells were analyzed using the following antibodies: phycoerythrin (PE)-conjugated mouse anti-human CD34 (BD Biosciences), FITC-conjugated mouse anti-human CD45 (BD Biosciences), and FITC-conjugated mouse anti-human CD38 (BD Biosciences). Isotypic mouse IgG1n antibodies conjugated to either PE or FITC were used as negative controls (BD Biosciences). Fluorescence-activated cell sorting (BD FACSAria) was used to isolate CD34
À / CD45 + , and CD34 + /CD38 À cells (Fig. 1) .
Whole BM obtained from gfp transgenic mice was used as the source of all murine progenitor cell types and analyzed using the following antibodies: PE-conjugated anti-mouse Flk1 (VEGFR2, Ly-73; BD Biosciences), PE-conjugated anti-mouse Sca1 (Ly-6A/E; BD Biosciences), allophycocyanin-conjugated anti-mouse Gr1 (Ly-6G; BD Biosciences), and PE-conjugated rat anti-mouse VEGFR1 (Flt1; R&D Systems). Isotypic mouse IgG1n antibodies conjugated to either PE, FITC (BD Biosciences), or allophycocyanin (R&D Systems) were used as negative controls. Fluorescence-activated cell sorting (BD FACSAria) of freshly isolated whole mouse BM was used to isolate Flk1 + , Sca1 + /Gr1 + , Sca1 À /Gr1 + , and Flt1 + cells (Fig. 1) . The significance of these human and mouse lineages is described in Table 2 . 6 cells/0.3 mL Matrigel; BD Biosciences). One week following tumor cell inoculation, one of the BM-derived mouse progenitor subpopulations or Ad5/F35-infected human subpopulations was separately injected intravenously into a Ewing's tumor-bearing mouse. Mice were euthanized 1 wk later, and tumors were resected, placed in OCT compound, snap frozen in liquid nitrogen, and stored at À80jC.
Immunohistochemistry
For in vitro analysis of EPC differentiation, chamber slides (see above) were fixed in acetone and incubated with mouse anti-human CD31 (DakoCytomation). For in vivo detection of mouse platelet-endothelial cell adhesion molecule (mCD31), gfp, hVEC, a-SMA, desmin, platelet-derived growth factor receptor-h, CD14, or F4/80, frozen tissue sections were fixed in acetone, blocked using 4% fish gelatin in PBS, and incubated with the appropriate primary antibody. The following antibodies were used: rat anti-mouse CD31/PECAM (BD Biosciences), rabbit anti-gfp (Santa Cruz Biotechnology), mouse anti-hVEC (Chemicon International, Inc.), mouse anti-SMA (Abcam), rabbit anti-desmin (Abcam), rabbit antiplatelet-derived growth factor receptor-h (Santa Cruz Biotechnology), mouse anti-CD14 (Abcam), and rat anti-mouse F4/80 (Serotec). When using mouse monoclonal antibodies, slides were preblocked overnight with F(ab) fragment (Jackson ImmunoResearch Laboratories, Inc.) before incubation with primary antibody. The following secondary antibodies were used: goat anti-rat Alexa Fluor 488, goat anti-rabbit Alexa Fluor 594, goat anti-rabbit Alexa Fluor 488, or goat antimouse Alexa Fluor 488 (Invitrogen). All antibodies were diluted in PBS containing 4% fish gelatin. Hoechst 33342 dye (Molecular Probes) was used to stain cell nuclei. Fluorescent images were captured at 10Â (eyepiece) and 10Â or 20Â (objective) with Optimas imaging software.
For confocal microscopy, the following secondary antibodies were used: goat anti-mouse Cy-3 [Cy-3 -conjugated AffiniPure F(ab ¶) 2 fragment goat anti-mouse IgG + IgM, Jackson ImmunoResearch Laboratories], goat anti-mouse Cy-5 (Jackson ImmunoResearch Laboratories), goat anti-rabbit Cy-3 (Jackson ImmunoResearch Laboratories), goat anti-rabbit Cy-5 (Jackson ImmunoResearch Laboratories), goat anti-rat Cy-3 (Jackson ImmunoResearch Laboratories), and goat anti-rat Cy-5 (Jackson ImmunoResearch Laboratories). Sytox Green (Invitrogen) was used to stain cell nuclei. Images were collected using a Zeiss laser confocal microscope (Carl Zeiss MicroImaging, Inc.).
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